Fig. 3: MEKi and CDK4/6i lead to RTKs reactivation. | Cancer Gene Therapy

Fig. 3: MEKi and CDK4/6i lead to RTKs reactivation.

From: A multi-omics integrative approach unravels novel genes and pathways associated with senescence escape after targeted therapy in NRAS mutant melanoma

Fig. 3

A Summary of significantly deregulated kinases. B Kinase activities after MEKi and CDK4/6i. ERK1/2 inhibition leads to RTKs activation. Rreceptors names are colored according to the enriched pathways. C Phylogenetic tree for SKMEL30 on day 1. The size of the leafs represents the “Median Final Score”, a score greater than 1.2 indicates a significant change between conditions. The color of the branches and leaves shows the “Median Kinase Statistic”, which is the difference in kinase activity. Circles highlight RTKs contributing to enriched pathways. D, E Activity of ERK5 in the senescent and adaptative cell lines. D Zoom on the MAPK pathway showing the deregulation of ERK5 (MAPK7) in MELJUSO cell line. E same for the SKMEL30 cell line.

Back to article page